Lafora Disease: A Case Report and Evolving Treatment Advancements
Abstract
:1. Introduction
2. Patient and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kälviäinen, R. Progressive Myoclonus Epilepsies. Semin. Neurol. 2015, 35, 293–299. [Google Scholar] [CrossRef] [PubMed]
- Nitschke, F.; Ahonen, S.J.; Nitschke, S.; Mitra, S.; Minassian, B.A. Lafora disease—From pathogenesis to treatment strategies. Nat. Rev. Neurol. 2018, 14, 606–617. [Google Scholar] [CrossRef]
- Berkovic, S.F.; Andermann, F.; Carpenter, S.; Wolfe, L.S. Progressive myoclonus epilepsies: Specific causes and diagnosis. N. Engl. J. Med. 1986, 315, 296–305. [Google Scholar] [CrossRef]
- Lafora, G.R.; Glueck, B. Beitrag zur Histopathologie der myoklonischen Epilepsie. Z. Die Gesamte Neurol. Psychiatr. 1911, 6, 1–14. [Google Scholar] [CrossRef]
- Heycoptenhamm, V.; De Jager, H. Progressive myoclonus epilepsy with Lafora bodies. Clinical-pathological features. Epilepsia 1963, 4, 95–119. [Google Scholar]
- Pondrelli, F.; Muccioli, L.; Licchetta, L.; Mostacci, B.; Zenesini, C.; Tinuper, P.; Vignatelli, L.; Bisulli, F. Natural history of Lafora disease: A prognostic systematic review and individual participant data meta-analysis. Orphanet J. Rare Dis. 2021, 16, 362. [Google Scholar] [CrossRef]
- Minassian, B.A.; Lee, J.R.; Herbrick, J.A.; Huizenga, J.; Soder, S.; Mungall, A.J.; Dunham, I.; Gardner, R.; Fong, C.Y.G.; Carpenter, S.; et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 1998, 20, 171–174. [Google Scholar] [CrossRef]
- Chan, E.M.; Young, E.J.; Ianzano, L.; Munteanu, I.; Zhao, X.; Christopoulos, C.C.; Avanzini, G.; Elia, M.; Ackerley, C.A.; Jovic, N.J.; et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet. 2003, 35, 125–127. [Google Scholar] [CrossRef]
- Couarch, P.; Vernia, S.; Gourfinkel-An, I.; Lesca, G.; Gataullina, S.; Fedirko, E.; Trouillard, O.; Depienne, C.; Dulac, O.; Steschenko, D.; et al. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism. J. Mol. Med. 2011, 89, 915–925. [Google Scholar] [CrossRef]
- Gentry, M.S.; Worby, C.A.; Dixon, J.E. Insights into Lafora disease: Malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc. Natl. Acad. Sci. USA 2005, 102, 8501–8506. [Google Scholar] [CrossRef]
- Kumarasinghe, L.; Xiong, L.; Garcia-Gimeno, M.A.; Lazzari, E.; Sanz, P.; Meroni, G. TRIM32 and Malin in Neurological and Neuromuscular Rare Diseases. Cells 2021, 10, 820. [Google Scholar] [CrossRef] [PubMed]
- Minassian, B.A.; Ianzano, L.; Meloche, M.; Andermann, E.; Rouleau, G.A.; Delgado-Escueta, A.V.; Scherer, S.W. Mutation spectrum and predicted function of laforin in Lafora’s progressive myoclonus epilepsy. Neurology 2000, 55, 341–346. [Google Scholar] [CrossRef] [PubMed]
- Mitra, S.; Gumusgoz, E.; Minassian, B.A. Lafora disease: Current biology and therapeutic approaches. Rev. Neurol. 2022, 178, 315–325. [Google Scholar] [CrossRef]
- Parihar, R.; Rai, A.; Ganesh, S. Lafora disease: From genotype to phenotype. J. Genet. 2018, 97, 611–624. [Google Scholar] [CrossRef] [PubMed]
- Tang, X.; Li, X.; Chen, Y.; Wu, D. Compound heterozygosity for novel variations of the NHLRC1 Gene in a family with Lafora disease. Clin. Neurol. Neurosurg. 2022, 218, 107255. [Google Scholar] [CrossRef]
- Turnbull, J.; Tiberia, E.; Striano, P.; Genton, P.; Carpenter, S.; Ackerley, C.A.; Minassian, B.A. Lafora disease. Epileptic Disord. 2016, 18, 38–62. [Google Scholar] [CrossRef]
- Pondrelli, F.; Minardi, R.; Muccioli, L.; Zenesini, C.; Vignatelli, L.; Licchetta, L.; Mostacci, B.; Tinuper, P.; Vander Kooi, C.W.; Gentry, M.S.; et al. Prognostic value of pathogenic variants in Lafora Disease: Systematic review and meta-analysis of patient-level data. Orphanet J. Rare Dis. 2023, 18, 263. [Google Scholar] [CrossRef]
- Masson, E.; Zou, W.B.; Génin, E.; Cooper, D.N.; Le Gac, G.; Fichou, Y.; Pu, N.; Rebours, V.; Férec, C.; Liao, Z.; et al. Expanding ACMG variant classification guidelines into a general framework. Hum. Genom. 2022, 16, 31. [Google Scholar] [CrossRef]
- Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–423. [Google Scholar] [CrossRef]
- Bektaş, Ö.; Yılmaz, A.; Okcu, A.H.; Teber, S.; Aksoy, E.; Deda, G. A type of progressive myoclonic epilepsy, Lafora disease: A case report. East. J. Med. 2013, 18, 34–36. [Google Scholar]
- Al Mufargi, Y.; Qureshi, A.; Al Asmi, A. Lafora Disease: Report of a Rare Entity. Cureus 2020, 12, e6793. [Google Scholar] [CrossRef]
- Gökdemir, S.; Çağlayan, H.; Kızıltan, M.; Karaağaç, N.; Leblebici, C.; Yeni, S.N. Presentation of an unusual patient with Lafora disease. Epileptic Disord. 2012, 14, 94–98. [Google Scholar] [CrossRef] [PubMed]
- Cenacchi, G.; Papa, V.; Costa, R.; Pegoraro, V.; Marozzo, R.; Fanin, M.; Angelini, C. Update on polyglucosan storage diseases. Virchows Arch. 2019, 475, 671–686. [Google Scholar] [CrossRef] [PubMed]
- Andrade, D.M.; Ackerley, C.A.; Minett, T.S.C.; Teive, H.A.G.; Bohlega, S.; Scherer, S.W.; Minassian, B.A. Skin biopsy in Lafora disease: Genotype-phenotype correlations and diagnostic pitfalls. Neurology 2003, 61, 1611–1614. [Google Scholar] [CrossRef]
- Lesca, G.; Boutry-Kryza, N.; De Toffol, B.; Milh, M.; Steschenko, D.; Lemesle-Martin, M.; Maillard, L.; Foletti, G.; Rudolf, G.; Nielsen, J.E.; et al. Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease. Epilepsia 2010, 51, 1691–1698. [Google Scholar] [CrossRef] [PubMed]
- Brewer, M.K.; Machio-Castello, M.; Viana, R.; Wayne, J.L.; Kuchtová, A.; Simmons, Z.R.; Sternbach, S.; Li, S.; García-Gimeno, M.A.; Serratosa, J.M.; et al. An empirical pipeline for personalized diagnosis of Lafora disease mutations. iScience 2021, 24, 103276. [Google Scholar] [CrossRef] [PubMed]
- Nitschke, F.; Wang, P.; Schmieder, P.; Girard, J.M.; Awrey, D.E.; Wang, T.; Israelian, J.; Zhao, X.; Turnbull, J.; Heydenreich, M.; et al. Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease. Cell Metab. 2013, 17, 756–767. [Google Scholar] [CrossRef]
- Nitschke, F.; Sullivan, M.A.; Wang, P.; Zhao, X.; Chown, E.E.; Perri, A.M.; Israelian, L.; Juana-López, L.; Bovolenta, P.; Rodríguez de Córdoba, S.; et al. Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease. EMBO Mol. Med. 2017, 9, 906–917. [Google Scholar] [CrossRef]
- Tagliabracci, V.S.; Turnbull, J.; Wang, W.; Girard, J.M.; Zhao, X.; Skurat, A.V.; Delgado-Escueta, A.V.; Minassian, B.A.; Depaoli-Roach, A.A.; Roach, P.J. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc. Natl. Acad. Sci. USA 2007, 104, 19262–19266. [Google Scholar] [CrossRef]
- Ganesh, S.; Delgado-Escueta, A.V.; Sakamoto, T.; Avila, M.R.; Machado-Salas, J.; Hoshii, Y.; Akagi, T.; Gomi, H.; Suzuki, T.; Amano, K.; et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet. 2002, 11, 1251–1262. [Google Scholar] [CrossRef]
- Tiberia, E.; Turnbull, J.; Wang, T.; Ruggieri, A.; Zhao, X.C.; Pencea, N.; Israelian, J.; Wang, Y.; Ackerley, C.A.; Wang, P.; et al. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease. J. Biol. Chem. 2012, 287, 25650–25659. [Google Scholar] [CrossRef]
- DePaoli-Roach, A.A.; Tagliabracci, V.S.; Segvich, D.M.; Meyer, C.M.; Irimia, J.M.; Roach, P.J. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to Lafora bodies and the accumulation of insoluble laforin. J. Biol. Chem. 2010, 285, 25372–25381. [Google Scholar] [CrossRef]
- Sullivan, M.A.; Nitschke, S.; Skwara, E.P.; Wang, P.; Zhao, X.; Pan, X.S.; Chown, E.E.; Wang, T.; Perri, A.M.; Lee, J.P.Y.; et al. Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases. Cell Rep. 2019, 27, 1334–1344.e6. [Google Scholar] [CrossRef]
- Carpenter, S.; Karpati, G.; Andermann, F.; Jacob, J.C.; Andermann, E. Lafora’s disease: Peroxisomal storage in skeletal muscle. Neurology 1974, 24, 531–538. [Google Scholar] [CrossRef] [PubMed]
- Coleman, D.L.; Gambetti, P.; Mauro, S.D.; Blume, R.E. Muscle in Lafora disease. Arch. Neurol. 1974, 31, 396–406. [Google Scholar] [CrossRef] [PubMed]
- Neville, H.E.; Brooke, M.H.; Austin, J.H. Studies in myoclonus epilepsy. (Lafora body form). IV. Skeletal muscle abnormalities. Arch. Neurol. 1974, 30, 466–474. [Google Scholar] [CrossRef] [PubMed]
- Iannaccone, S.; Zucconi, M.; Quattrini, A.; Nemni, R.; Comola, M.; Taccagni, L.; Smirne, S. Early detection of skin and muscular involvement in Lafora disease. J. Neurol. 1991, 238, 217–220. [Google Scholar] [CrossRef] [PubMed]
- Turnbull, J.; Girard, J.M.; Lohi, H.; Chan, E.M.; Wang, P.; Tiberia, E.; Omer, S.; Ahmed, M.; Bennett, C.; Chakrabarty, A.; et al. Early-onset Lafora body disease. Brain 2012, 135 Pt 9, 2684–2698. [Google Scholar] [CrossRef] [PubMed]
- Jara-Prado, A.; Ochoa, A.; Alonso, M.E.; Lima Villeda, G.A.; Fernández-Valverde, F.; Ruano-Calderón, L.; Vargas-Cañas, S.; Durón, R.M.; Delgado-Escueta, A.V.; Martínez-Juárez, I.E. Late onset Lafora disease and novel EPM2A mutations: Breaking paradigms. Epilepsy Res. 2014, 108, 1501–1510. [Google Scholar] [CrossRef] [PubMed]
- Sun, Y.; Zhou, Z.; Wang, Q.; Yan, J.; Zhang, Z.; Cui, T. MRI characteristics due to gene mutations in a Chinese pedigree with Lafora disease. Mol. Genet. Genom. Med. 2023, 11, e2228. [Google Scholar] [CrossRef]
- Farah, B.L.; Yen, P.M.; Koeberl, D.D. Links between autophagy and disorders of glycogen metabolism—Perspectives on pathogenesis and possible treatments. Mol. Genet. Metab. 2020, 129, 3–12. [Google Scholar] [CrossRef]
- Puri, R.; Suzuki, T.; Yamakawa, K.; Ganesh, S. Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease. Hum. Mol. Genet. 2012, 21, 175–184. [Google Scholar] [CrossRef]
- Criado, O.; Aguado, C.; Gayarre, J.; Duran-Trio, L.; Garcia-Cabrero, A.M.; Vernia, S.; San Millán, B.; Heredia, M.; Romá-Mateo, C.; Mouron, S.; et al. Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Hum. Mol. Genet. 2012, 21, 1521–1533. [Google Scholar] [CrossRef]
- McCarron, E.P. Valproate induced carnitine deficiency and hyperammonaemia. Clin. Med. 2023, 23, 429. [Google Scholar] [CrossRef] [PubMed]
- Melegh, B.; Trombitás, K. Valproate Treatment Induces Lipid Globule Accumulation with Ultrastructural Abnormalities of Mitochondria in Skeletal Muscle. Neuropediatrics 1997, 28, 257–261. [Google Scholar] [CrossRef]
- Garyali, P.; Siwach, P.; Singh, P.K.; Puri, R.; Mittal, S.; Sengupta, S.; Parihar, R.; Ganesh, S. The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system. Hum. Mol. Genet. 2009, 18, 688–700. [Google Scholar] [CrossRef]
- Garyali, P.; Segvich, D.M.; DePaoli-Roach, A.A.; Roach, P.J. Protein degradation and quality control in cells from laforin and malin knockout mice. J. Biol. Chem. 2014, 289, 20606–20614. [Google Scholar] [CrossRef] [PubMed]
- Duran, J.; Guinovart, J.J. Brain glycogen in health and disease. Mol. Asp. Med. 2015, 46, 70–77. [Google Scholar] [CrossRef] [PubMed]
- Tarnopolsky, M.A. Myopathies Related to Glycogen Metabolism Disorders. Neurotherapeutics 2018, 15, 915–927. [Google Scholar] [CrossRef]
- Colombo, I.; Pagliarani, S.; Testolin, S.; Salsano, E.; Napoli, L.M.; Bordoni, A.; Salani, S.; D’Adda, E.; Morandi, L.; Farina, L.; et al. Adult polyglucosan body disease: Clinical and histological heterogeneity of a large Italian family. Neuromuscul. Disord. 2015, 25, 423–428. [Google Scholar] [CrossRef] [PubMed]
- Paradas, C.; Akman, H.O.; Ionete, C.; Lau, H.; Riskind, P.N.; Jones, D.E.; Smith, T.W.; Hirano, M.; Dimauro, S. Branching enzyme deficiency: Expanding the clinical spectrum. JAMA Neurol. 2014, 71, 41–47. [Google Scholar] [CrossRef]
- Turnbull, J.; Epp, J.R.; Goldsmith, D.; Zhao, X.; Pencea, N.; Wang, P.; Frankland, P.W.; Ackerley, C.A.; Minassian, B.A. PTG protein depletion rescues malin-deficient Lafora disease in mouse. Ann. Neurol. 2014, 75, 442–446. [Google Scholar] [CrossRef]
- Kecmanović, M.; Keckarević-Marković, M.; Keckarević, D.; Stevanović, G.; Jović, N.; Romac, S. Genetics of Lafora progressive myoclonic epilepsy: Current perspectives. Appl. Clin. Genet. 2016, 9, 49–53. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.; Sethi, I.; Francheschetti, S.; Riggio, C.; Avanzini, G.; Yamakawa, K.; Delgado-Escueta, A.V.; Ganesh, S. Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora’s progressive myoclonic epilepsy. J. Med. Genet. 2006, 43, e48. [Google Scholar] [CrossRef]
- Casciato, S.; Gambardella, S.; Mascia, A.; Quarato, P.P.; D’Aniello, A.; Ackurina, Y.; Albano, V.; Fornai, F.; Scala, S.; Di Gennaro, G. Severe and rapidly-progressive Lafora disease associated with NHLRC1 mutation: A case report. Int. J. Neurosci. 2017, 127, 1150–1153. [Google Scholar] [CrossRef] [PubMed]
- Bisulli, F.; Muccioli, L.; d’Orsi, G.; Canafoglia, L.; Freri, E.; Licchetta, L.; Mostacci, B.; Riguzzi, P.; Pondrelli, F.; Avolio, C.; et al. Treatment with metformin in twelve patients with Lafora disease. Orphanet J. Rare Dis. 2019, 14, 149. [Google Scholar] [CrossRef] [PubMed]
- Schorlemmer, K.; Bauer, S.; Belke, M.; Hermsen, A.; Klein, K.M.; Reif, P.S.; Oertel, W.H.; Kunz, W.S.; Knake, S.; Rosenow, F.; et al. Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease). Epilepsy Behav. Case Rep. 2013, 1, 118–121. [Google Scholar] [CrossRef]
- Assenza, G.; Nocerino, C.; Tombini, M.; Di Gennaro, G.; D’Aniello, A.; Verrotti, A.; Marrelli, A.; Ricci, L.; Lanzone, J.; Di Lazzaro, V.; et al. Perampanel improves cortical myoclonus and disability in progressive myoclonic epilepsies: A case series and a systematic review of the literature. Front. Neurol. 2021, 12, 630366. [Google Scholar] [CrossRef]
- Dirani, M.; Nasreddine, W.; Abdulla, F.; Beydoun, A. Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav. Case Rep. 2014, 29, 164–166. [Google Scholar] [CrossRef]
- Goldsmith, D.; Minassian, B.A. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 2016, 62, 132–135. [Google Scholar] [CrossRef]
- Manini, A.; Abati, E.; Nuredini, A.; Corti, S.; Comi, G.P. Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence. Front. Neurol. 2022, 12, 814174. [Google Scholar] [CrossRef] [PubMed]
- Parente, V.; Corti, S. Advances in spinal muscular atrophy therapeutics. Ther. Adv. Neurol. Disord. 2018, 11, 1756285618754501. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Tai, P.W.L.; Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 2019, 18, 358–378. [Google Scholar] [CrossRef] [PubMed]
- Deverman, B.E.; Ravina, B.M.; Bankiewicz, K.S.; Paul, S.M.; Sah, D.W.Y. Gene therapy for neurological disorders: Progress and prospects. Nat. Rev. Drug Discov. 2018, 17, 641–659. [Google Scholar] [CrossRef] [PubMed]
- Morris, G.; Schorge, S. Gene Therapy for Neurological Disease: State of the Art and Opportunities for Next-generation Approaches. Neuroscience 2022, 490, 309–314. [Google Scholar] [CrossRef] [PubMed]
- Vemana, H.P.; Saraswat, A.; Bhutkar, S.; Patel, K.; Dukhande, V.V. A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine 2021, 16, 1081–1095. [Google Scholar] [CrossRef]
- Varea, O.; Guinovart, J.J.; Duran, J. Malin restoration as proof of concept for gene therapy for Lafora disease. Brain Commun. 2022, 4, fcac168. [Google Scholar] [CrossRef]
- Varea, O.; Duran, J.; Aguilera, M.; Prats, N.; Guinovart, J.J. Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity. Neurobiol. Dis. 2021, 147, 105173. [Google Scholar] [CrossRef]
- Nitschke, S.; Chown, E.E.; Zhao, X.; Gabrielian, S.; Petković, S.; Guisso, D.R.; Perri, A.M.; Wang, P.; Ahonen, S.; Nitschke, F.; et al. An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice. J. Biol. Chem. 2021, 296, 100150. [Google Scholar] [CrossRef]
- Pederson, B.A.; Turnbull, J.; Epp, J.R.; Weaver, S.A.; Zhao, X.; Pencea, N.; Roach, P.J.; Frankland, P.W.; Ackerley, C.A.; Minassian, B.A. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Ann. Neurol. 2013, 74, 297–300. [Google Scholar] [CrossRef]
- Guan, L.; Han, Y.; Yang, C.; Lu, S.; Du, J.; Li, H.; Lin, J. CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders. Mol. Neurobiol. 2022, 59, 968–982. [Google Scholar] [CrossRef] [PubMed]
- Gumusgoz, E.; Guisso, D.R.; Kasiri, S.; Wu, J.; Dear, M.; Verhalen, B.; Nitschke, S.; Mitra, S.; Nitschke, F.; Minassian, B.A. Targeting Gys1 with AAV-SaCas9 decreases pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and Lafora disease mouse models. Neurotherapeutics 2021, 18, 1414–1425. [Google Scholar] [CrossRef]
- Ahonen, S.; Nitschke, S.; Grossman, T.R.; Kordasiewicz, H.; Wang, P.; Zhao, X.; Guisso, D.R.; Kasiri, S.; Nitschke, F.; Minassian, B.A. Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease. Brain 2021, 144, 2985–2993. [Google Scholar] [CrossRef]
- Douillard-Guilloux, G.; Raben, N.; Takikita, S.; Ferry, A.; Vignaud, A.; Guillet-Deniau, I.; Favier, M.; Thurberg, B.L.; Roach, P.J.; Caillaud, C.; et al. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum. Mol. Genet. 2010, 19, 684–696. [Google Scholar] [CrossRef] [PubMed]
- Pederson, B.A.; Chen, H.; Schroeder, J.M.; Shou, W.; DePaoli-Roach, A.A.; Roach, P.J. Abnormal cardiac development in the absence of heart glycogen. Mol. Cell Biol. 2004, 24, 7179–7187. [Google Scholar] [CrossRef] [PubMed]
- Kollberg, G.; Tulinius, M.; Gilljam, T.; Ostman-Smith, I.; Forsander, G.; Jotorp, P.; Oldfors, A.; Holme, E. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N. Engl. J. Med. 2007, 357, 1507–1514. [Google Scholar] [CrossRef] [PubMed]
- Austin, G.L.; Simmons, Z.R.; Klier, J.E.; Rondon, A.; Hodges, B.L.; Shaffer, R.; Aziz, N.M.; McKnight, T.R.; Pauly, J.R.; Armstrong, D.D.; et al. Central nervous system delivery and biodistribution analysis of an antibody-enzyme fusion for the treatment of Lafora disease. Mol. Pharm. 2019, 16, 3791–3801. [Google Scholar] [CrossRef]
- Brewer, M.K.; Uittenbogaard, A.; Austin, G.L.; Segvich, D.M.; DePaoli-Roach, A.; Roach, P.J.; McCarthy, J.J.; Simmons, Z.R.; Brandon, J.A.; Zhou, Z.; et al. Targeting pathogenic Lafora bodies in Lafora disease using an antibody-enzyme fusion. Cell Metab. 2019, 30, 689–705.e6. [Google Scholar] [CrossRef]
- Zhou, Z.; Austin, G.L.; Shaffer, R.; Armstrong, D.D.; Gentry, M.S. Antibody-mediated enzyme therapeutics and applications in glycogen storage diseases. Trends Mol. Med. 2019, 25, 1094–1109. [Google Scholar] [CrossRef]
- Israelian, L.; Wang, P.; Gabrielian, S.; Zhao, X.; Minassian, B.A. Ketogenic diet reduces Lafora bodies in murine Lafora disease. Neurol. Genet. 2020, 6, e533. [Google Scholar] [CrossRef]
- Sánchez-Elexpuru, G.; Serratosa, J.M.; Sanz, P.; Sánchez, M.P. 4-phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease. Neuroreport 2017, 28, 268–271. [Google Scholar] [CrossRef] [PubMed]
- Berthier, A.; Payá, M.; García-Cabrero, A.M.; Ballester, M.I.; Heredia, M.; Serratosa, J.M.; Sánchez, M.P.; Sanz, P. Pharmacological interventions to ameliorate neuropathological symptoms in a mouse model of Lafora disease. Mol. Neurobiol. 2016, 53, 1296–1309. [Google Scholar] [CrossRef] [PubMed]
- Burgos, D.F.; Machío-Castello, M.; Iglesias-Cabeza, N.; Giráldez, B.G.; González-Fernández, J.; Sánchez-Martín, G.; Sánchez, M.P.; Serratosa, J.M. Early Treatment with Metformin Improves Neurological Outcomes in Lafora Disease. Neurotherapeutics 2023, 20, 230–244. [Google Scholar] [CrossRef] [PubMed]
- Molla, B.; Heredia, M.; Sanz, P. Modulators of neuroinflammation have a beneficial effect in a Lafora disease mouse model. Mol. Neurobiol. 2021, 58, 2508–2522. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ferrari Aggradi, C.R.; Rimoldi, M.; Romagnoli, G.; Velardo, D.; Meneri, M.; Iacobucci, D.; Ripolone, M.; Napoli, L.; Ciscato, P.; Moggio, M.; et al. Lafora Disease: A Case Report and Evolving Treatment Advancements. Brain Sci. 2023, 13, 1679. https://doi.org/10.3390/brainsci13121679
Ferrari Aggradi CR, Rimoldi M, Romagnoli G, Velardo D, Meneri M, Iacobucci D, Ripolone M, Napoli L, Ciscato P, Moggio M, et al. Lafora Disease: A Case Report and Evolving Treatment Advancements. Brain Sciences. 2023; 13(12):1679. https://doi.org/10.3390/brainsci13121679
Chicago/Turabian StyleFerrari Aggradi, Carola Rita, Martina Rimoldi, Gloria Romagnoli, Daniele Velardo, Megi Meneri, Davide Iacobucci, Michela Ripolone, Laura Napoli, Patrizia Ciscato, Maurizio Moggio, and et al. 2023. "Lafora Disease: A Case Report and Evolving Treatment Advancements" Brain Sciences 13, no. 12: 1679. https://doi.org/10.3390/brainsci13121679
APA StyleFerrari Aggradi, C. R., Rimoldi, M., Romagnoli, G., Velardo, D., Meneri, M., Iacobucci, D., Ripolone, M., Napoli, L., Ciscato, P., Moggio, M., Comi, G. P., Ronchi, D., Corti, S., & Abati, E. (2023). Lafora Disease: A Case Report and Evolving Treatment Advancements. Brain Sciences, 13(12), 1679. https://doi.org/10.3390/brainsci13121679